Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
August 19, 2008

Mitsubishi Tanabe Signs On Cellumen to Develop Toxicity-Prediction Panels to Enhance Early Drug Discovery

  • Cellumen has agreed to develop panels of biomarkers that identify toxicity early in the drug development process for Mitsubishi Tanabe Pharma.
    Cellumen provides cellular systems biology toxicity profiling services to identify toxic compounds in late primary screening through early preclinical phases. By integrating optimal cells, panels of functional biomarkers, and classifier software, its CellCiphr technology is able to create a safety risk index for compounds and help researchers predict potential rodent or human toxicity, the company explains.